- Home
- TOVX
as 04-24-2025 4:00pm EST
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 4.0M | IPO Year: | 2006 |
| Target Price: | $6.00 | AVG Volume (30 days): | 21.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -19.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.96 - $12.25 | Next Earning Date: | 05-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Theriva Biologics Inc. News
TOVX Breaking Stock News: Dive into TOVX Ticker-Specific Updates for Smart Investing
GlobeNewswire
15 days ago
Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
GlobeNewswire
25 days ago
Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company’s Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
GlobeNewswire
a month ago
Theriva™ Biologics to Present at the 2025 NeauxCancer Conference
ACCESS Newswire
a month ago
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
GlobeNewswire
2 months ago
Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results
GlobeNewswire
2 months ago
Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual
GlobeNewswire
5 months ago
Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer
Associated Press Finance
5 months ago
Theriva Biologics: Q3 Earnings Snapshot
Compare TOVX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TOVX Theriva Biologics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.